[1]郭富饶,李启富,徐智新.血浆肾素测定方法的新进展及临床意义[J].国际内分泌代谢杂志,2021,41(06):628-631.[doi:10.3760/cma.j.cn121383-20210315-03038]
 Guo Furao,Li Qifu,Xu Zhixin..Advances and clinical value of plasma renin measurement[J].International Journal of Endocrinology and Metabolism,2021,41(06):628-631.[doi:10.3760/cma.j.cn121383-20210315-03038]
点击复制

血浆肾素测定方法的新进展及临床意义()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年06期
页码:
628-631
栏目:
综述
出版日期:
2021-12-20

文章信息/Info

Title:
Advances and clinical value of plasma renin measurement
作者:
郭富饶1李启富2徐智新2
1重庆市巴南区人民医院检验科 401320; 2重庆医科大学附属第一医院内分泌科 400016
Author(s):
Guo Furao1 Li Qifu2 Xu Zhixin2.
1Department of Laboratory medicine, People's Hospital of Chongqing Banan District, Chongqing 401320, China; 2Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016,China
关键词:
原发性醛固酮增多症 肾素浓度 肾素活性
Keywords:
Primary aldosteronism Plasma renin concentration Plasma renin activity
DOI:
10.3760/cma.j.cn121383-20210315-03038
摘要:
原发性醛固酮增多症(简称原醛症)是常见的继发性高血压之一,占所有高血压患者的5%~10%。临床上常用血浆醛固酮/肾素比值(ARR)筛查原醛症,因此,血浆肾素测定的准确性十分重要。既往采用放免法测定血浆肾素活性(PRA)。近年来,建立了基于化学发光法的直接肾素浓度(PRC)检测,并以其便利性、较好的特异性和敏感性获得了广泛应用。本文重点介绍PRC测定方法,并对其在原醛症筛查中的应用价值进行概述,同时就目前存在的相关问题进行探讨。
Abstract:
Primary aldosteronism(PA)is a common cause of secondary hypertension and accounts for 5%~10% of all hypertensive patients. The plasma aldosterone/renin ratio is clinically used for screening PA, so the accuracy of renin measurement is essential. In the past, plasma renin level was assessed by plasma renin activity(PRA). Recently, direct assay of plasma renin concentration(PRC)has been developed and widely used due to its convenience, satisfactory specificity and sensitivity. This review briefly introduces the methods of renin measurement and summarizes the application of PRC measurement in the screening for PA, and looks forward to the application prospect of PRC in the future.

参考文献/References:

[1] Viola A,Monticone S,Burrello J,et al.Renin and aldosterone measurements in the management of arterial hypertension[J].Horm Metab Res,2015,47(6):418-426.DOI:10.1055/s-0035-1548868.
[2] Arnal JF,Cudek P,Plouin PF,et al.Recent advances in the investigation of the renin-angiotensin and cardiac natriuretic systems in patients with chronic heart insufficiency[J].Arch Mal Coeur Vaiss,1991,84(9):1273-1280.
[3] Plouin PF,Cudek P,Arnal JF,et al.Immunoradiometric assay of active renin versus determination of plasma renin activity in the clinical investigation of hypertension,congestive heart failure,and liver cirrhosis[J].Horm Res,1990,34(3-4):138-141.DOI:10.1159/000181813.
[4] Sealey JE,Gordon RD,Mantero F.Plasma renin and aldosterone measurements in low renin hypertensive states[J].Trends Endocrinol Metab,2005,16(3):86-91.DOI:10.1016/j.tem.2005.02.006.
[5] Galen FX,Devaux C,Atlas S,et al.New monoclonal antibodies directed against human renin.Powerful tools for the investigation of the renin system[J].J Clin Invest,1984,74(3):723-735.DOI:10.1172/JCI111488.
[6] Plouin PF,Cudek P,Arnal JF,et al.Immunoradiometric assay of active renin versus determination of plasma renin activity in the clinical investigation of hypertension,congestive heart failure,and liver cirrhosis[J].Horm Res,1990,34(3-4):138-141.DOI:10.1159/000181813.
[7] Sealey JE,Trenkwalder P,Gahnem F,et al.Plasma renin methodology:inadequate sensitivity and accuracy of direct renin assay for clinical applications compared with the traditional enzymatic plasma renin activity assay[J].J Hypertens,1995,13(1):27-30; discussion 31.
[8] Perschel FH,Schemer R,Seiler L,et al.Rapid screening test for primary hyperaldosteronism:ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays[J].Clin Chem,2004,50(9):1650-1655.DOI:10.1373/clinchem.2004.033159.
[9] Funder JW,Carey RM,Mantero F,et al.The management of primary aldosteronism:case detection,diagnosis,and treatment:An Endocrine Society Clinical Practice Guideline[J].J Clin Endocrinol Metab,2016,101(5):1889-1916.DOI:10.1210/jc.2015-4061.
[10] Morganti A,European study group for the validation of DiaSorin LIAISON Direct Renin Assay.A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin[J].J Hypertens,2010,28(6):1307-1312.DOI:10.1097/HJH.0b013e32833857ad.
[11] Lonati C,Bassani N,Gritti A,et al.Measurement of plasma renin concentration instead of plasma renin activity decreases the positive aldosterone-to-renin ratio tests in treated patients with essential hypertension[J].J Hypertens,2014,32(3):627-634.DOI:10.1097/HJH.0000000000000076.
[12] Dorrian CA,Toole BJ,Alvarez-Madrazo S,et al.A screening procedure for primary aldosteronism based on the Diasorin Liaison automated chemiluminescent immunoassay for direct renin[J].Ann Clin Biochem,2010,47(Pt 3):195-199.DOI:10.1258/acb.2010.009230.
[13] Wu VC,Kuo CC,Chang HW,et al.Diagnosis of primary aldosteronism:comparison of post-captopril active renin concentration and plasma renin activity[J].Clin Chim Acta,2010,411(9-10):657-663.DOI:10.1016/j.cca.2010.01.027.
[14] Unger N,Lopez Schmidt I,Pitt C,et al.Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass[J].Eur J Endocrinol,2004,150(4):517-523.DOI:10.1530/eje.0.1500517.
[15] Rossi GP,Barisa M,Belfiore A,et al.The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma[J].J Hypertens,2010,28(9):1892-1899.DOI:10.1097/HJH.0b013e32833d2192.
[16] Glinicki P,Jeske W,Bednarek-Papierska L,et al.The ratios of aldosterone / plasma renin activity(ARR)versus aldosterone / direct renin concentration(ADRR)[J].J Renin Angiotensin Aldosterone Syst,2015,16(4):1298-1305.DOI:10.1177/1470320313519487.
[17] Burrello J,Monticone S,Buffolo F,et al.Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism[J].J Hypertens,2016,34(5):920-927.DOI:10.1097/HJH.0000000000000880.
[18] Li T,Ma Y,Zhang Y,et al.Feasibility of screening primary aldosteronism by aldosterone-to-direct renin concentration ratio derived from chemiluminescent immunoassay measurement:diagnostic accuracy and cutoff value[J].Int J Hypertens,2019,2019:2195796.DOI:10.1155/2019/2195796.
[19] Ma L,Song Y,Mei M,et al.Age-related cutoffs of plasma aldosterone/renin concentration for primary aldosteronism screening[J].Int J Endocrinol,2018,2018:8647026.DOI:10.1155/2018/8647026.
[20] Nishikawa T,Omura M,Satoh F,et al.Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009[J].Endocr J,2011,58(9):711-721.DOI:10.1507/endocrj.ej11-0133.
[21] Young WF Jr.Diagnosis and treatment of primary aldosteronism:practical clinical perspectives[J].J Intern Med,2019,285(2):126-148.DOI:10.1111/joim.12831.
[22] Wang K,Hu J,Yang J,et al.Development and validation of criteria for sparing confirmatory tests in diagnosing primary aldosteronism[J].J Clin Endocrinol Metab,2020,105(7):dgaa282.DOI:10.1210/clinem/dgaa282.

相似文献/References:

[1]高海静,温俊平.肾上腺醛固酮腺瘤术后临床转归的影响因素[J].国际内分泌代谢杂志,2016,36(01):58.[doi:10.3760/cma.j.issn.1673-4157.2016.01.015]
 Gao Haijing,Wen Junping..Influence factors of postoperative clinical outcomes for patients with adrenal aldosteronoma[J].International Journal of Endocrinology and Metabolism,2016,36(06):58.[doi:10.3760/cma.j.issn.1673-4157.2016.01.015]
[2]钟珊,宋筱筱,徐小红.原发性醛固酮增多症分型诊断研究进展[J].国际内分泌代谢杂志,2020,40(05):327.[doi:10.3760/cma.j.cn121383-20200203-02006]
 Zhong Shan,Song Xiaoxiao,Xu Xiaohong.Research progress of subtype diagnosis in primary hyperaldosteronism[J].International Journal of Endocrinology and Metabolism,2020,40(06):327.[doi:10.3760/cma.j.cn121383-20200203-02006]
[3]郑爱琳,宋颖,罗蓉,等.关于原发性醛固酮增多症诊治的常见误区[J].国际内分泌代谢杂志,2021,41(02):73.[doi:10.3760/cma.j.cn121383-20210119-01054]
 Zheng Ailin,Song Ying,Luo Rong,et al.Misunderstandings in the diagnosis and treatment of primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2021,41(06):73.[doi:10.3760/cma.j.cn121383-20210119-01054]
[4]王慧萍,童安莉.原发性醛固酮增多症相关的基因突变研究进展[J].国际内分泌代谢杂志,2021,41(02):87.[doi:10.3760/cma.j.cn121383-20200706-07013]
 Wang Huiping,Tong Anli..Research progress on gene mutation related primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2021,41(06):87.[doi:10.3760/cma.j.cn121383-20200706-07013]
[5]许媛 许岚 张丽华 李启富 杨淑敏.中国原发性醛固酮增多症诊断现状调查研究[J].国际内分泌代谢杂志,2022,42(04):288.[doi:10.3760/cma.j.cn121383-20201221-12058]
 Xu Yuan,Xu Lan,Zhang Lihua,et al.Investigation on current status of diagnosis of primary aldosteronism in China[J].International Journal of Endocrinology and Metabolism,2022,42(06):288.[doi:10.3760/cma.j.cn121383-20201221-12058]
[6]谢梦晨,郭洋洋,黄金慧,等.原发性醛固酮增多症基因型与临床表型关系的研究进展[J].国际内分泌代谢杂志,2023,43(03):216.[doi:10.3760/cma.j.cn121383-20220307-03015]
 Xie Mengchen,Guo Yangyang,Huang Jinhui,et al.Association of genotype and clinical phenotype of primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2023,43(06):216.[doi:10.3760/cma.j.cn121383-20220307-03015]
[7]王敏 杨宇宏 孙敏.原发性醛固酮增多症的组织病理学新分类及其意义[J].国际内分泌代谢杂志,2023,43(05):372.[doi:10.3760/cma.j.cn121383-20220604-06010]
 Wang Min,Yang Yuhong,Sun Min..New histopathological classification of primary aldosteronism and its significance[J].International Journal of Endocrinology and Metabolism,2023,43(06):372.[doi:10.3760/cma.j.cn121383-20220604-06010]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81800701); 重庆市社会事业与民生保障科技创新专项子课题(cstc2016shms-ztzx1003)
通信作者:徐智新,Email: 1637438709@qq.com
更新日期/Last Update: 2021-12-10